Clinical Study Results
Research Sponsor: MedImmune LLC, a wholly owned subsidiary
of AstraZeneca
Drug Studied: MEDI1873
Study Title: A study to find out about the safety of MEDI1873 in
participants with advanced solid tumors
Thank you
Thank you for taking part in the clinical study for the study drug MEDI1873.
MedImmune LLC sponsored this study and believes it is important to share the
results. An independent non-profit organization called CISCRP helped prepare this
summary of the study results for you.
If you participated in the study and have questions about the results, please speak
with the study doctor or staff at your study site.
Who took part in the study?
The researchers asked for the help of men and women with advanced solid
tumors. The participants in this study were 32 to 81 years old when they joined and
had already tried at least 1 treatment for their tumors.
The participants in this study had 1 of 3 types of advanced solid tumors:
• Squamous cell carcinoma of the head and neck, also called SCCHN
• Non-small cell lung cancer, also called NSCLC
• Colorectal cancer, also called CRC
The study included 40 participants in the United States.
1